Menglin Jiang, Lanting Wang, Sheng-an Chen, Fanping Yang, H. Xiong, Yu Su, Huizhong Zhu, Z. Qi, Shengying Qin, Xiaoqun Luo, Q. Xing
{"title":"HLA-B* 46:01与汉族皮肤药物不良反应的关系","authors":"Menglin Jiang, Lanting Wang, Sheng-an Chen, Fanping Yang, H. Xiong, Yu Su, Huizhong Zhu, Z. Qi, Shengying Qin, Xiaoqun Luo, Q. Xing","doi":"10.1097/JBR.0000000000000011","DOIUrl":null,"url":null,"abstract":"Abstract The majority of patients who experience cutaneous adverse drug reactions (cADRs) concurrently receive multiple medications, meaning that the causative drug remains unidentified. We explored the association between human leukocyte antigen (HLA) alleles and cADRs, regardless of the allergenic drug, to investigate whether different drug-induced cADRs were associated with the same or similar risk alleles in a Han Chinese population. We genotyped a sample of 146 cADR patients and 230 population controls from the same hospital and systematically analyzed the association between HLA Class I genes and cADRs. The carrier frequency of HLA-B*46:01 in cADR patients was found to be significantly higher than that in population controls (P = .0021, odds ratio [OR] = 2.18, 95% confidence interval [CI]: 1.33–2.58). Subgroup analysis showed that HLA-B*46:01 was significantly associated with urticaria and erythema multiforme (P = .0077, OR = 2.53, 95% CI: 1.30–4.91; and P = .0049, OR = 2.77, 95% CI: 1.39–5.50, respectively). Furthermore, a significant association was also detected between HLA-A*02:01 and erythema multiforme (P = .0038, OR = 2.65, 95% CI: 1.31–5.33). This study is the first to demonstrate that HLA-B*46:01 is a risk allele for cADRs in a Han Chinese population, indicating that screening for HLA-B*46:01 prior to the administration of medication may predict the risk of developing cADRs.","PeriodicalId":150904,"journal":{"name":"Journal of Bio-X Research","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2018-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":"{\"title\":\"Association between HLA-B*46: 01 and cutaneous adverse drug reactions in Han Chinese\",\"authors\":\"Menglin Jiang, Lanting Wang, Sheng-an Chen, Fanping Yang, H. Xiong, Yu Su, Huizhong Zhu, Z. Qi, Shengying Qin, Xiaoqun Luo, Q. Xing\",\"doi\":\"10.1097/JBR.0000000000000011\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Abstract The majority of patients who experience cutaneous adverse drug reactions (cADRs) concurrently receive multiple medications, meaning that the causative drug remains unidentified. We explored the association between human leukocyte antigen (HLA) alleles and cADRs, regardless of the allergenic drug, to investigate whether different drug-induced cADRs were associated with the same or similar risk alleles in a Han Chinese population. We genotyped a sample of 146 cADR patients and 230 population controls from the same hospital and systematically analyzed the association between HLA Class I genes and cADRs. The carrier frequency of HLA-B*46:01 in cADR patients was found to be significantly higher than that in population controls (P = .0021, odds ratio [OR] = 2.18, 95% confidence interval [CI]: 1.33–2.58). Subgroup analysis showed that HLA-B*46:01 was significantly associated with urticaria and erythema multiforme (P = .0077, OR = 2.53, 95% CI: 1.30–4.91; and P = .0049, OR = 2.77, 95% CI: 1.39–5.50, respectively). Furthermore, a significant association was also detected between HLA-A*02:01 and erythema multiforme (P = .0038, OR = 2.65, 95% CI: 1.31–5.33). This study is the first to demonstrate that HLA-B*46:01 is a risk allele for cADRs in a Han Chinese population, indicating that screening for HLA-B*46:01 prior to the administration of medication may predict the risk of developing cADRs.\",\"PeriodicalId\":150904,\"journal\":{\"name\":\"Journal of Bio-X Research\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2018-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"2\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Bio-X Research\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1097/JBR.0000000000000011\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Bio-X Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1097/JBR.0000000000000011","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 2
摘要
大多数发生皮肤药物不良反应(cADRs)的患者同时接受多种药物治疗,这意味着致病药物仍未确定。我们探讨了人类白细胞抗原(HLA)等位基因与cadr之间的关系,而不考虑致敏药物,以研究不同药物诱导的cadr是否与汉族人群中相同或相似的风险等位基因相关。我们对来自同一医院的146例cADR患者和230例人群对照进行了基因分型,系统地分析了HLA I类基因与cADR之间的关系。发现cADR患者HLA-B*46:01的携带者频率显著高于人群对照组(P =。0021,优势比[OR] = 2.18, 95%可信区间[CI]: 1.33-2.58)。亚组分析显示,HLA-B*46:01与荨麻疹和多形性红斑显著相关(P =。0077, or = 2.53, 95% ci: 1.30-4.91;和P =。0049, OR = 2.77, 95% CI分别为1.39 ~ 5.50)。此外,HLA-A*02:01与多形性红斑之间也存在显著相关性(P =。0038, or = 2.65, 95% ci: 1.31-5.33)。本研究首次证实HLA-B*46:01是中国汉族人群中发生cadr的风险等位基因,表明在给药前筛查HLA-B*46:01可预测发生cadr的风险。
Association between HLA-B*46: 01 and cutaneous adverse drug reactions in Han Chinese
Abstract The majority of patients who experience cutaneous adverse drug reactions (cADRs) concurrently receive multiple medications, meaning that the causative drug remains unidentified. We explored the association between human leukocyte antigen (HLA) alleles and cADRs, regardless of the allergenic drug, to investigate whether different drug-induced cADRs were associated with the same or similar risk alleles in a Han Chinese population. We genotyped a sample of 146 cADR patients and 230 population controls from the same hospital and systematically analyzed the association between HLA Class I genes and cADRs. The carrier frequency of HLA-B*46:01 in cADR patients was found to be significantly higher than that in population controls (P = .0021, odds ratio [OR] = 2.18, 95% confidence interval [CI]: 1.33–2.58). Subgroup analysis showed that HLA-B*46:01 was significantly associated with urticaria and erythema multiforme (P = .0077, OR = 2.53, 95% CI: 1.30–4.91; and P = .0049, OR = 2.77, 95% CI: 1.39–5.50, respectively). Furthermore, a significant association was also detected between HLA-A*02:01 and erythema multiforme (P = .0038, OR = 2.65, 95% CI: 1.31–5.33). This study is the first to demonstrate that HLA-B*46:01 is a risk allele for cADRs in a Han Chinese population, indicating that screening for HLA-B*46:01 prior to the administration of medication may predict the risk of developing cADRs.